Zonisamide launched for Parkinson's in Japan
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) has launched the anticonvulsant agent Trerief (zonisamide) as a therapy for Parkinson's disease in Japan, its first market for this use. The product has been marketed in the country since 1989 as Excegran, for the treatment of epilepsy, a use for which it is also approved in more than 30 other countries.